Antiverse

Antiverse is a Cardiff-based AI-driven antibody discovery company founded in 2017. The company has built a platform that designs therapeutic-grade antibodies against some of medicine's most difficult drug targets — G-protein coupled receptors (GPCRs) and ion channels — which are implicated in over 200 diseases but have fewer than ten FDA-approved antibody treatments.

Antiverse's platform uses machine learning models trained on seven years of proprietary data to generate antibody candidate sequences computationally. This lab-in-the-loop cycle allows Antiverse to produce therapeutic-grade antibodies against difficult targets in approximately four months, compared to the one-to-three-year timelines associated with conventional approaches. Antiverse raised $9.3 million in a Series A in March 2026, led by Soulmates Ventures. Total funding now exceeds $20 million since founding.